Evaluation of the HIV lipodystrophy case definition in a placebo-controlled, 144-week study in antiretroviral-naive adults

Antiviral Therapy

Volumn 11, Issue 2, 2006, Pages 179-186

  Law, Matthew ^a   Puls, Rebekah ^a   Cheng, Andrew K ^b   Cooper, David A ^a   Carr, Andrew ^c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b GILEAD SCIENCES   (United States)

^c ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PLACEBO; STAVUDINE; TENOFOVIR DISOPROXIL;

ADULT; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE SEVERITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; OUTCOME ASSESSMENT; PARAMETER; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

ADULT; AGING; ANTI-HIV AGENTS; DENSITOMETRY, X-RAY; FEMALE; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; PLACEBOS; RISK FACTORS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33645528266     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 2003, 17(Suppl 1):S141-148.
2. Miller J, Carr A, Emery S, et al. HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med 2003, 4:293-301.
3. Bernasconi E, Boubaker K, Junghans C, et al. Swiss HIV Cohort Study. Abnormalities or body fat distribution in HIV-infected persons treated with antiretroviral drugs: the Swiss HIV Cohort Study. J AIDS 2002, 31:50-55.
4. Lichtenstein KA, Ward DJ, Moorman AC, et al. HIV Outpatient Study Investigators. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001, 15:1389-1398.
5. Gallant JE, Staszewski S, Pozniak AL, et al. 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients; a 3-year randomized trial. JAMA 2004, 292:191-201.
6. Carr A, Workman C, Smith D, et al. for the Mitochondrial Toxicity (MITOX) Study Group. Abacavir substitution for nucleoside analogs in patients with HFV lipoatrophy: a randomized trial. JAMA 2002, 288:207-215.
7. Carr A, Hudson J, Chuah J, et al. for the PIILR investigators. HIV protease inhibitor substitution in patients with lipodystrophy: a randomised, multicentre, open-label study. AIDS 2001, 15:1811-1822.
8. Martinez E, Mocroft A, Garcia-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001, 357:592-598.
9. Mallon PWG, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 2003, 17:971-999.
10. Fellay J, Boubaker K, Ledergerber B, et al. Swiss HIV Cohort Study. Prevalence of adverse events associated with potent antiretroviral treatment. Lancet 2001, 358:1322-1327.
11. Carr A, Emery SE, Law M, Puls R, Lundgren JD, Powderly WG. HIV Lipodystrophy Case Definition Study Group. An objective case definition of lipodystrophy in HIV-infected adults. Lancet 2003, 361:726-735.
12. Carr A, Law M. HIV Lipodystrophy Case Definition Study Group. An objective lipodystrophy severity grading scale using the lipodystrophy case definition score. J AIDS 2003, 33:571-576.
13. Puls RL, Law M, Freund J, et al. The effect of centralized body composition data analysis on an objective case definition of HIV lipodystrophy. Antivir Ther 2002, 7(Suppl 3):80.
14. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-58.
15. Gervasoni C, Ridolfo AL, Trifirò G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 1999, 13:465-472.
16. Carr A, Samaras K, Thorisdottir A, Kaufmann G, Chisholm DJ, Cooper DA. Diagnosis, prediction and natural course of HIV protease inhibitor-associated lipodystrophy, hyperlipidaemia and diabetes mellitus. Lancet 1999, 353:2893-2899.
17. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999, 13:1659-1667.
18. Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000, 14:F25-F32.
19. Thiebaut R, Daucourt V, Mercie P, et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Clin Infect Dis 2000; 31:1482-1487.
20. Heath K, Hogg RS, Chan KJ, et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS 2001, 15:231-240.
21. Lichtenstein KA, Delaney KM, Armon C, et al.; HIV Outpatient Study Investigators. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J AIDS 2003, 32:48-56.
22. Carr A, Workman C, Carey D, et al.; Rosey investigators. No effect of rosiglitazone for HIV-1 lipoatrophy: a randomised, double-blind, placebo-controlled trial. Lancet 2004, 363:429-438.
23. Dubé MP, Parker RA, Tebas P, et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 2005; 19:1807-1818.